第五部分是对公司治理的有效性评价指标体系的修正。
Part 5 is on amendment of system of indicators of assessment of effectiveness of corporate governance.
主要评价指标：在24周的治疗期间评估评估奥曲肽植入物的有效性、安全性和耐受性。
Main Outcome Measure: to evaluate the efficacy, safety, and tolerability of the octreotide implant during 24 weeks of treatment.
但在信号强度几乎相同的条件下，这一评价指标的有效性较低。
But on the condition that the strength of signals is almost equal, the validity of the appraisal index is rather low.
应用推荐